A Single-arm, Open Label Clinical Study to Evaluate the Safety and Efficacy of VGO-Cs01p in Patients With CD7-positive Relapsed/Refractory Acute T-lymphoblastic Leukemia
Latest Information Update: 05 Mar 2025
At a glance
- Drugs VGO Cs01p (Primary)
- Indications Precursor T-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 05 Mar 2025 New trial record